Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

EIGR - Eiger BioPharmaceuticals, Inc.

Close
1.725
-0.175   -10.145%

Share volume: 137,824
Last Updated: Wed 10 Apr 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.90
-0.18
-9.21%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 50%
Dept financing 18%
Liquidity 69%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$1.72
P/E Ratio 
0.00
DAY RANGE
$1.66 - $1.90
EPS 
-$50.78
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
1.481 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: David A. Cory
Region: US
Website: eigerbio.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Eiger BioPharmaceuticals, Inc. focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors.

Recent news